ClinicalTrials.gov

History of Changes for Study: NCT04330534
First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH
Latest version (submitted February 15, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 March 30, 2020 None (earliest Version on record)
2 February 18, 2021 Recruitment Status, Study Status, Contacts/Locations and Study Design
3 February 15, 2022 Study Status and Contacts/Locations
Comparison Format:

Scroll up to access the controls

Study NCT04330534
Submitted Date:  March 30, 2020 (v1)

Open or close this module Study Identification
Unique Protocol ID: BCX9930-101
Brief Title: First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH
Official Title: A Phase 1 Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BCX9930 in Healthy Subjects and in Subjects With Paroxysmal Nocturnal Hemoglobinuria
Secondary IDs:
Open or close this module Study Status
Record Verification: March 2020
Overall Status: Recruiting
Study Start: March 3, 2020
Primary Completion: October 2020 [Anticipated]
Study Completion: June 2021 [Anticipated]
First Submitted: March 23, 2020
First Submitted that
Met QC Criteria:
March 30, 2020
First Posted: April 1, 2020 [Actual]
Last Update Submitted that
Met QC Criteria:
March 30, 2020
Last Update Posted: April 1, 2020 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: BioCryst Pharmaceuticals
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: This is a 3-part Phase 1 dose-ranging study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single (Part 1) and multiple (Part 2) ascending doses of BCX9930 in healthy subjects and in subjects with paroxysmal nocturnal hemoglobinuria (PNH; Part 3). Pharmacokinetics is an analysis of how the body handles the study drug BCX9930 and pharmacodynamics is an analysis of the activity that the study drug BCX9930 may have in the body.
Detailed Description:

Up to 6 sequential ascending dose cohorts are planned to be dosed in a sequential manner in Part 1 of the study. Eight subjects will be treated with a single dose of the study drug per dose cohort (6 subjects per cohort will receive BCX9930 and 2 subjects per cohort will receive matching placebo). Escalation to the next higher dose level will occur only after completion of a review of clinical safety and pharmacokinetics by the Sponsor and PI.

Up to 7 ascending, multiple dose cohorts will be enrolled in a sequential manner in Part 2 of the study. In Cohorts 1 through 3, twelve subjects will be treated with either a 7-day or 14-day course of study drug (10 subjects per cohort will receive BCX9930 and 2 subjects per cohort will receive matching placebo) administered orally. In Cohorts 4 through 7, twelve subjects will be treated with a 3-day course of study drug (10 subjects per cohort will receive BCX9930 and 2 subjects per cohort will receive matching placebo) administered orally. The daily dose may be split into 2 times daily (BID) or 3 times daily (TID) dosing for the multiple ascending dose part as needed. Escalation to the next higher dose level in Part 2 will occur only after completion of a review of clinical safety and pharmacokinetics by the Sponsor and PI.

Part 3 of the study consists of up to 2 sequential ascending multiple dose cohorts of up to 8 subjects; each cohort may enroll up to 4 subjects with PNH who are naïve to both eculizumab and ravulizumab and up to 4 subjects with PNH who are currently being treated with either eculizumab or ravulizumab. In each cohort, subjects will receive one daily dose of BCX9930 on Days 1 to 14 and a higher daily dose on Days 15 to 28. Cohort 2 will start after independent data monitoring committee (DMC) review of Cohort 1 data and communication of their evaluation to Part 3 investigators. In South Africa, subjects that have clinical benefit from BCX9930 will be allowed to continue dosing for up to 48 weeks.

Open or close this module Conditions
Conditions: Paroxysmal Nocturnal Hemoglobinuria
Keywords: Paroxysmal Nocturnal Hemoglobinuria
first-in-human
Factor D
complement inhibitor
alternative pathway inhibitor
BioCryst
proof-of-concept
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 1/Phase 2
Interventional Study Model: Single Group Assignment
Each cohort in Part 3 is enrolled as a single group; Parts 1 and 2 follow a parallel study model.
Number of Arms: 2
Masking: None (Open Label)
Allocation: Non-Randomized
Enrollment: 148 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: BCX9930
Parts 1, 2 and 3
Drug: BCX9930
BCX9930 capsules for oral administration
Placebo Comparator: Placebo
Parts 1 and 2 only
Drug: Placebo
placebo to match BCX9930 capsules for oral administration
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Incidence of graded treatment-emergent adverse events
[ Time Frame: Part 1: Day 16 ]

2. Incidence of graded treatment-emergent adverse events
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

3. Incidence of graded treatment-emergent adverse events
[ Time Frame: Part 3:Day 44 or Week 50 (South Africa only) ]

4. Incidence of graded laboratory chemistry abnormalities
[ Time Frame: Part 1: Day 16 ]

5. Incidence of graded laboratory chemistry abnormalities
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

6. Incidence of graded laboratory chemistry abnormalities
[ Time Frame: Part 3:Day 44 or Week 50 (South Africa only) ]

7. Incidence of graded urinalysis abnormalities
[ Time Frame: Part 1: Day 16 ]

8. Incidence of graded urinalysis abnormalities
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

9. Incidence of graded urinalysis abnormalities
[ Time Frame: Part 3: Day 44 or Week 50 (South Africa only) ]

10. Incidence of graded coagulation abnormalities
[ Time Frame: Part 1: Day 16 ]

11. Incidence of graded coagulation abnormalities
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

12. Incidence of graded coagulation abnormalities
[ Time Frame: Part 3: Day 44 or Week 50 (South Africa only) ]

13. Incidence of graded hematology abnormalities
[ Time Frame: Part 1: Day 16 ]

14. Incidence of graded hematology abnormalities
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

15. Incidence of graded hematology abnormalities
[ Time Frame: Part 3: Day 44 or Week 50 (South Africa only) ]

16. Change from baseline in blood pressure
[ Time Frame: Part 1: Day 16 ]

17. Change from baseline in blood pressure
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

18. Change from baseline in blood pressure
[ Time Frame: Part 3: Day 44 or Week 50 (South Africa only) ]

19. Change from baseline in temperature
[ Time Frame: Part 1: Day 16 ]

20. Change from baseline in temperature
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

21. Change from baseline in temperature
[ Time Frame: Part 3: Day 44 or Week 50 (South Africa only) ]

22. Change from baseline in heart rate
[ Time Frame: Part 1: Day 16 ]

23. Change from baseline in heart rate
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

24. Change from baseline in heart rate
[ Time Frame: Part 3: Day 44 or Week 50 (South Africa only) ]

25. Change from baseline in respiratory rate
[ Time Frame: Part 3: Day 44 or Week 50 (South Africa only) ]

26. Change in Electrocardiogram (PR interval)
[ Time Frame: Part 1: Day 16 ]

27. Change in Electrocardiogram (PR interval)
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

28. Change in Electrocardiogram (PR interval)
[ Time Frame: Part 3: Day 44 or Week 50 (South Africa only) ]

29. Change in Electrocardiogram (QRS interval)
[ Time Frame: Part 1: Day 16 ]

30. Change in Electrocardiogram (QRS interval)
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

31. Change in Electrocardiogram (QRS interval)
[ Time Frame: Part 3: Day 44 or Week 50 (South Africa only) ]

32. Change in Electrocardiogram (RR interval)
[ Time Frame: Part 1: Day 16 ]

33. Change in Electrocardiogram (RR interval)
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

34. Change in Electrocardiogram (RR interval)
[ Time Frame: Part 3:Day 44 or Week 50 (South Africa only) ]

35. Change in Electrocardiogram (QT interval)
[ Time Frame: Part 1: Day 16 ]

36. Change in Electrocardiogram (QT interval)
[ Time Frame: Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration) ]

37. Change in Electrocardiogram (QT interval)
[ Time Frame: Part 3:Day 44 or Week 50 (South Africa only) ]

Secondary Outcome Measures:
1. Plasma BCX9930 Cmax
[ Time Frame: plasma PK parameters are based on blood sampling through Day 4 for Part 1; through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and through Day 28 for Part 3 ]

2. Plasma BCX9930 Tmax
[ Time Frame: plasma PK parameters are based on blood sampling through Day 4 for Part 1; through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and through Day 28 for Part 3 ]

3. Plasma BCX9930 AUCinf
[ Time Frame: plasma PK parameters are based on blood sampling through Day 4 for Part 1 ]

4. Plasma BCX9930 t1/2
[ Time Frame: plasma PK parameters are based on blood sampling through Day 4 for Part 1; through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and through Day 28 for Part 3 ]

5. Plasma BCX9930 AUCtau
[ Time Frame: plasma PK parameters are based on blood sampling through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and through Day 28 for Part 3 ]

6. Serum AP complement activity
[ Time Frame: Part 1:through Study Day 4; through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and Part 3 through Day 28 or Week 48 (South Africa only) ]

7. Plasma Factor Bb
[ Time Frame: Part 1:through Study Day 4; through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and Part 3 through Day 28 or Week 48 (South Africa only) ]

8. Number of blood transfusions
[ Time Frame: Part 3:baseline through Day 28 or Week 50 (South Africa only) ]

9. Lactate dehydrogenase
[ Time Frame: Part 3: absolute and change from baseline through Day 28 or Week 50 (South Africa only) ]

10. Hemoglobin
[ Time Frame: Part 3: absolute and change from baseline through Day 28 or Week 50 (South Africa only) ]

11. Absolute reticulocyte count
[ Time Frame: Part 3: values and change from baseline through Day 28 or Week 50 (South Africa only) ]

12. Haptoglobin
[ Time Frame: Part 3: absolute and change from baseline through Day 28 or Week 50 (South Africa only) ]

Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based: Yes
Accepts Healthy Volunteers: Yes
Criteria:

Key Inclusion Criteria (Parts 1, 2, and 3):

  • Able to provide written informed consent
  • Acceptable birth control measures for male subjects and women of childbearing potential
  • Is expected to adequately comply with required study procedures and restrictions

Key Inclusion Criteria (Parts 1 and 2):

  • Body mass index (BMI) of 18.0 to 32.0 kg/m2.
  • Males and non-pregnant, non-lactating females age 18 to 55 years.
  • Part 2: Must have recent vaccination against Neisseria meningitidis and must be negative for colonisation by Neisseria meningitidis

Key Inclusion Criteria (Part 3 only):

  • Male or non-pregnant, non-lactating female subjects ≥ 18 years old
  • Have been diagnosed with PNH and have laboratory values indicative of active PNH
  • Subjects naïve to both eculizumab and ravulizumab treatment, who have no access to, or are considered unsuitable for proven effective alternative options as per the local standard of care OR subjects currently receiving treatment with eculizumab or ravulizumab have been on a stable dose of eculizumab or ravulizumab for 6 months
  • Must have recent vaccination against Neisseria meningitidis

Key Exclusion Criteria (Parts 1 and 2):

  • Clinically significant medical history, current medical or psychiatric condition that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject.
  • Clinically significant ECG finding or laboratory/urinalysis abnormality
  • Use of prescription or over the counter medication within 14 days of dosing
  • Participation in any other investigational drug study within 90 days of screening
  • Recent or current history of alcohol or drug abuse within the last 12 months
  • Current smokers and those who have smoked within the last 12 months
  • Positive serology for HIV or active infection with HBV or HCV
  • Pregnant or nursing
  • Donation or loss of greater than 400 mL of blood within 3 months
  • History of severe hypersensitivity to any drug or Neisseria meningitidis vaccines (Part 2)
  • Subject has recently received a live attenuated vaccine within 30 days of dosing or another type of vaccine within 14 days of Day 1

Key Exclusion Criteria (Part 3):

  • Apart from a diagnosis of PNH, any clinically significant medical or psychiatric condition or medical history, other than those associated with PNH disease, that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study or participation would increase the risk for that subject
  • Active bacterial infection
  • Hereditary complement deficiency
  • History of hematopoietic stem cell /marrow transplantation
  • Current participation in any other investigational drug study or participation in an investigational drug study within 30 days of the screening visit
  • History of meningococcal disease
  • Positive drugs of abuse screen at screening visit
  • Pregnant, planning to become pregnant, or having been pregnant within 90 days of Day 1, or lactating
  • History of severe hypersensitivity to any drug
Open or close this module Contacts/Locations
Central Contact Person: Study Director
Telephone: +1 919 859 1302
Email: clinicaltrials@biocryst.com
Study Officials: Antionio Risitano
Principal Investigator
University of Naples
Locations: South Africa
Study Site
[Recruiting]
Bloemfontein, South Africa
Study Site
[Recruiting]
Pretoria, South Africa
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services